Paul Angulo: Clinician investigator  by George, Jacob & Bugianesi, Elisabetta
ObituaryPaul Angulo: Clinician investigatorClinician investigators are a rare breed, and ones that do it with
aplomb, even more hard to ﬁnd. Early this year, the Hepatology
community learnt about the sad and sudden demise of one of
its foremost clinician investigators, Paul Angulo. As most of the
readership will be aware, Paul was an outstanding investigator
with an international reputation on the clinical aspects of fatty
liver disease. At the time of his death, Paul was a Professor of
Medicine and Section Chief of Hepatology at the University of
Kentucky, a position he held for 5 years. His prior work and the
pathway to a proliferative publishing career, was fostered at
the Mayo Clinic, the institution that ﬁrst described the clinical
entity of non-alcoholic steatohepatitis, 30 years ago.
Paul did his undergraduate studies in Medicine at the
Universidad Michoacana de San Nicolás de Hildalgo in Mexico,
before undertaking gastroenterology training at the Instituto
Nacional de la Nutricion Salvador Zubirán in Mexico City. He sub-
sequently moved to the Mayo Clinic, Rochester, MN to undertake
a postdoctoral research fellowship under the mentorship of Keith
Lindor. From there on, Paul established himself as a highly suc-
cessful and renowned clinical investigator, with over 110 pub-
lished papers, 46 chapters and review articles and 22 editorials
and correspondences. To this, Paul was successful in obtaining
highly competitive NIH R01 grants, and had numerous nationalJournal of Hepatology 20
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DDW, EASL and APASL. In terms of other service to the discipline
of Hepatology, Paul contributed on numerous committees includ-
ing the scientiﬁc committees of the NIDDK, the AASLD Annual
Meeting Education Committee, the AASLD Clinical Research
Committee and as liaison to the Hepatology Associates
Committee and to Special Interest Groups (SIG) on Steatosis
and Steatohepatitis, and Cholestatic Liver Disorders. Paul was
an Associate Editor for Liver International and on the editorial
board of a host of journals including Gastroenterology,
Hepatology and the Journal of Hepatology.
Paul is best known for his contributions in the ﬁeld of fatty
liver disease. These include studies on natural history, the histo-
logical course of NAFLD, intervention trials (ursodeoxycholic acid,
pentoxyfylline, ecosapentanoic acid, betaine), and on the role of
lifestyle intervention in children with NAFLD. In 2007, Paul led
the multinational multicentre collaborative study that developed
the NAFLD ﬁbrosis score, perhaps the most widely used and
accepted non-invasive scoring system for the disease. This group
led by Paul, not only developed the original score, but more
recently deﬁned that the score predicts the long-term outcomes
of people with the disease and is now in common use as an
App available on the web.
While Paul’s academic achievements speak for themselves,
much less is known about Paul as a person. For those of us who
knew him well, while an intensely private person, he was always
a tremendous and willing collaborator, happy to contribute to
scientiﬁc discourse and to share data. Paul was one of those rare
individuals, who was both enthusiastic and passionate about
clinical research, and as well, was able to put his efforts where
his passion lay, working ceaselessly to undertake analysis and
to get manuscripts to the required quality for submission. To
his students, he was a great mentor, leader and teacher, who
was willing to give his time to support and guide junior faculty.
Above all, it was great to have him as a friend, colleague and col-
laborator. The Hepatology community has lost at a young age,
one who contributed so much to our speciality, and to our
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